Tachycardia in hyperthyroidism: Not so common

Muriel Tania Go, Amrutha Mary George, Bettina Tahsin, Leon Fogelfeld

John H. Stroger Jr., Hospital of Cook County, Chicago, Illinois, United States of America
*lfogelfeld@cookcountyhhs.org

Abstract

Objective
The commonly held association of hyperthyroidism with sinus tachycardia and widened pulse pressure (PP) has not been reassessed in decades despite patients with hyperthyroidism in current practice not always present with these signs. The study objective was to assess prevalence and variability of sinus tachycardia and widened PP in present day among individuals with different degrees of hyperthyroidism.

Methods
Data was collected retrospectively from 248 adult patients in an outpatient setting with biochemical evidence of hyperthyroidism, recorded heart rate (HR) and blood pressure (BP) who were not treated with medications that can influence these parameters.

Results
Mean age was 42.0 ± 14.2 years with 66.9% being female. Median free thyroxine (fT4) level was 3.49 (IQR 2.42–4.58) ng/dL and thyroid stimulating hormone (TSH) 0.02 (IQR 0.01–0.03) mIU/L. Tachycardia, defined as HR >100 bpm, was present in 28.2%. In the lowest and highest fT4 quartiles, tachycardia was present in 16.4% and 38.7% respectively. Using logistic regression, tachycardia was associated with higher fT4 and diastolic BP. More lenient outcome of tachycardia with HR >90 bpm was seen in 47.2%. Widened PP, defined as >50 mmHg, was observed in 64.1% of patients and correlated with higher fT4 and BP.

Conclusions
Tachycardia is not a common feature of hyperthyroidism today. The relatively infrequent finding of tachycardia in this study compared to older studies may reflect differences in the way medicine is practiced today. The increased ordering of thyroid function tests most likely unmasked cases of mild or asymptomatic thyrotoxicosis. A widened PP was a more prevalent clinical finding in this study.
Introduction

Thyroid hormones are well known to have a significant impact on cardiac function through their effect on cardiac gene expression and sensitivity of the sympathetic system [1]. Extensive evidence indicates that even minimal but persistent changes in circulating thyroid hormone levels lead to changes in heart rate (HR) and contractility [2–4]. Consequently, excessive or deficient thyroid hormones lead to profound changes in cardiac function regulation and cardiovascular hemodynamics.

It is a well-established fact that hyperthyroidism enhances myocardial contractility resulting in increased stroke volume and reduces systemic vascular resistance [5]. This combined effect leads to a widened pulse pressure (PP) [6]. Sinus tachycardia, defined as a HR of >100 beats per minutes (bpm), is another common sign of hyperthyroidism present in 70–100% of patients [7–9]. However, the literature on this finding is from the 1980s with tachycardia inconsistently defined and, in some studies, reported as ≥ 90 bpm. In those studies, mean HR ranged from 95 to 105 bpm [7–9].

In our clinical practice, we noted the absence of sinus tachycardia in many newly diagnosed patients with untreated hyperthyroidism, even with elevated free thyroxine (fT4) levels more than two- to four-fold the upper limit of normal. This clinical observation together with the paucity of recent literature on this subject prompted us to explore the prevalence and range of variability of sinus tachycardia and PP in patients with hyperthyroidism of varying degrees of severity.

Methods

Study design

We undertook a retrospective cross-sectional study of adults who were biochemically hyperthyroid with available HR and blood pressure (BP) measurements. Data were obtained from the electronic medical records of outpatients seen in the Cook County Health System and John H. Stroger Jr Hospital of Cook County in Chicago, Illinois. Trained nursing staff in the various clinics using the same standard automated equipment measured the heart rate and blood pressure values. The study was approved by the hospital’s institutional review board committee with a consent waiver.

Inclusion and exclusion criteria

Inclusion criteria included adults >18 years old seen in the outpatient clinics during a two-year period who were biochemically hyperthyroid, defined as having a fT4 >21.1 pmol/L (reference range 7.9–21.1 pmol/L) and thyroid stimulating hormone (TSH) <0.1 mIU/L (reference range 0.34–5.60 mIU/L), and with available corresponding HR and BP measurements recorded within 30 days of thyroid test dates.

Exclusion criteria included patients treated with any of the following medications listed within 90 days of the thyroid tests: levothyroxine (LT4), beta-blockers, digoxin and other antihypertensive drugs including calcium channel blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, hydralazine, aldosterone receptor blockers and diuretics. Patients treated with methimazole (MMI) or propylthiouracil (PTU) within 30 days of the thyroid tests were also excluded from the study.

Study group

We obtained data from 141,439 observations of 59,400 patients who had thyroid function testing done during a two-year period (Fig 1). The study population was narrowed to 35,681
patients who had both TSH and fT4 levels and HR and BP measurements within 30 days of measuring the thyroid function tests (TFTs). Fig 1 further explains the exclusion steps based on LT4, beta-blockers, digoxin, and anti-hypertensive medications within 90 days of TFTs. Patients with normal or low fT4 (fT4 \leq 1.64 \text{ ng/dL}) and/or TSH \geq 0.1 \text{ mIU/mL} were also
excluded. The last exclusion factor was the use of anti-thyroid drugs within 30 days of TFTs. The final sample population was 248 patients. For each patient, a detailed chart review was performed, including confirmation of the diagnosis of hyperthyroidism based on laboratory values, functional imaging (if performed), and clinic notes. For patients with two or more documented HR and BP measurements during the clinic visit, the values were averaged.

### Outcomes

The main outcomes related to the levels of thyroid hormones were HR, BP, and PP. For HR, sinus tachycardia was defined as HR >100 bpm [10]. Previous literature has inconsistently defined tachycardia with mean HR ranging between 90–105 bpm [8–11]. Taking into account an inherent error of 5% in measurements, we calculated a second more lenient outcome of tachycardia with HR >90 bpm.

A widened PP was defined as >50 mmHg. Although there were no cutoff values delineating normal levels for different age groups, a widened PP of more than 50 mmHg has been suggested [12]. For older hypertensive individuals, a PP of >60 mmHg has been linked to increased cardiovascular disease-related mortality [13, 14]. We therefore defined pulse pressure of >60 mmHg as an elevated PP in this study.

### Statistical analysis

Baseline characteristics were presented as means ± SD for normally distributed values or as medians with interquartile ranges (IQR). Categorical data were presented by frequency and percentage. Comparisons between interquartile groups were made using ANOVA. To determine the relationship between variables, bivariate correlation, and multivariate linear and logistic regression analyses were used. Two-tailed P values less than 0.05 were considered statistically significant. Data were analyzed using IBM SPSS statistics, version 24.0.

### Results

The study group included 248 patients, 67.8% of whom were females (Table 1). Mean age was 42.0 ± 14.2 years ranging from 19–89 years of age. Median fT4 level was 3.49 (IQR 2.42–4.58) ng/dL and median TSH was 0.02 (IQR 0.01–0.03) mIU/L. Mean HR was 91.0 ± 19.2 bpm with

| Table 1. Clinical characteristics of the study group. |
|-----------------------------------------------------|
| Patients (N = 248) Range                           |
| Age (years)                                       | 42.0 ± 14.2 19–89 |
| Female, n (%)                                     | 168 (67.7) |
| fT4 (ng/dL)                                       | 3.49 (IQR 2.42–4.58) 1.65–6.00 |
| TSH (mIU/mL)                                      | 0.02 (0.01–0.03) 0.010–0.09 |
| Heart rate, bpm                                   | 91.0 ± 19.2 44–151 |
| Tachycardia, HR >100 bpm, n (%)                   | 70 (28.2) |
| HR >90 bpm, n (%)                                 | 117 (47.2) |
| Systolic BP, mm Hg                                | 126.2 ± 17.5 88–180 |
| Diastolic BP, mm Hg                               | 69.7 ± 12.0 15–121 |
| Pulse pressure, mm Hg                             | 56.5 ± 14.4 19–105 |
| Widened PP, >50 mm Hg, n (%)                      | 159 (64.1) |
| Elevated PP, >60 mm Hg, n (%)                     | 86 (34.7) |

Data presented as mean ± standard deviation (SD), number (percentage), or median (interquartile range).

https://doi.org/10.1371/journal.pone.0273724.t001
tachycardia defined as HR >100 bpm, present in 28.2%. HR >90 bpm was present in 47.2%.
The mean PP was 56.5 ± 14.4 mm Hg with 64.1% having a widened PP of >50 mm Hg.

The thyroid and cardiac values per fT4 quartile are shown in Table 2 with HR distribution across fT4 quartiles shown in Fig 2. In the first two quartiles, tachycardia was present in 16.4% and 23.8%, respectively, compared to 33.9% and 38.7% in the third and fourth quartile. There were statistically significant differences in HR between the quartiles by one-way ANOVA [F (3, 244) = 8.0, p < 0.001]. The interquartile variability range of heart rate within each fT4 quartile ranged from 20–28.5 bpm.

In bivariate correlation analysis, fT4 positively correlated with HR, PP and systolic BP, and negatively correlated with age (p < 0.005 for each variable). In multivariate regression analysis,
increased heart rate correlated with younger age ($p = 0.017$), higher fT4 ($p < 0.001$), and higher diastolic BP ($p < 0.001$) [$F (3, 244) = 17.21, p < 0.001, R^2 = 0.18$]. The presence of sinus tachycardia $>100$ bpm in logistic regression analysis correlated with higher fT4 (OR 1.03, 95% CI 1.01–1.05) and diastolic BP (OR 1.03, 95% CI 1.01–1.06).

A widened PP (Fig 3) was observed in more than 50% of patients in all quartiles and over 75% in the fourth quartile. In contrast, elevated PP ($>60$ mm Hg) was observed in fewer than 50% in the first three quartiles and 51.6% in the fourth quartile. There were statistically significant differences in pulse pressure between the quartiles based on one-way ANOVA [$F (3, 244) = 7.60, p < 0.001$].

Widening PP correlated with higher fT4 ($p = 0.005$), systolic BP ($p < 0.001$) and lower diastolic BP ($p = 0.030$) using bivariate correlation analysis.

**Discussion**

This study evaluated the prevalence and variability of tachycardia in patients with hyperthyroidism. The incidence of tachycardia defined as HR $>100$ bpm was 28.1% in this study, much lower than the incidence of 70–100% previously reported [7–9, 11, 15]. Given the inconsistent definitions of tachycardia in older studies, we calculated a second scenario of tachycardia with HR $>90$ bpm and still the incidence was fewer than half of patients.

In the hyperthyroid state, chronotropic alterations manifesting as sinus tachycardia, atrial fibrillation, and shortened PR interval, and inotropic alterations including increased cardiac index, stroke volume and pulse pressure have been well described [16–18]. Early literature with studies conducted between 1943 and 1945 found 72% of thyrotoxic patients had HR of
100–140 bpm [19]. This was comparable to later studies done from 1960–1988 which showed tachycardia in 70–84% of hyperthyroid patients [18]. In a more recent study conducted in a cohort of 3,049 patients [20], while the incidence of tachycardia was not measured, the incidence of other hyperadrenergic signs were 50% lower compared to the 1945 study. Due to a lack of recent literature, we studied the relative prevalence of cardiovascular signs in hyperthyroid patients.

Our study showed tachycardia was present in fewer than one-third of patients. Even if the heart rate threshold were to be lowered for better comparison to previous studies with inconsistent definitions of tachycardia, a little more than half of patients still had HR less than 90 bpm. This significant decline in the prevalence of tachycardia in recent times may be due to the increasing utilization of readily available and highly sensitive thyroid function assays [21, 22]. This widespread change in clinical practice may lead to diagnoses of hyperthyroidism in patients with fewer symptoms. In the earlier studies from 1940 to 1980, there may have been ascertainment bias where only patients who presented with symptoms and advanced thyrotoxicosis were subjected to the then cumbersome thyroid tests available, making tachycardia much more common during those times.

In this study, the level of fT4 was the major determinant of heart rate. However, even in the highest quartile of fT4, tachycardia occurred in only 40.0% of patients. If the HR threshold was lowered to >90 bpm, then the percentage increased to 63.1% in the fourth quartile. The inconsistent effect of hyperthyroidism on HR was also shown in hyperthyroid animal studies. Isolated heart preparations in different study settings noted tachycardia was abolished while the inotropic effect persisted [23–25]. In this study, as in other studies, older age was related to a lower heart rate [20, 26–28].

The hyperthyroid state causes predictable decreases in systemic vascular resistance and diastolic BP and increases in systolic BP and cardiac output [5, 29]. This leads to a widened PP which has been described in thyrotoxic patients in previous literature [30, 31]. In this study, 63.5% of patients and 78.5% in the highest fT4 quartile had widened PP. Based on these findings, one can postulate that a widened PP may be a useful physical finding in the clinical diagnosis of hyperthyroidism. Elevated PP (>60 mm Hg), which has been shown to be associated with heart failure and myocardial infarction [32, 33], was found in 33.8% of our patients and positively correlated with levels of fT4.

In this study, we found wide variabilities in heart rate and pulse pressure within each fT4 quartile, with interquartile ranges varying from 20 to 26 bpm for heart rate and 14 to 20 mm Hg for pulse pressure (Figs 2 and 3). In fact, in clinical practice, it has been found that the intensity of thyrotoxic symptoms and the level of thyroid hormones do not correlate so well [34]. Thyroid function test results may be markedly abnormal in patients exhibiting only mild symptoms, or conversely, mild to moderately abnormal levels can be seen in overtly symptomatic patients [11, 34]. This discrepancy may be secondary to the poor reflection of serum fT4 to the intracellular thyroid hormone concentrations [34], cellular variations in nuclear thyroid hormone receptor sensitivity [35], or differences in adrenergic-mediated hyperthyroid symptoms [36, 37]. However, new data suggests that clinical parameters such as cardiovascular disease had a stronger association of up to 50% with fT4 levels as compared to 23% with TSH levels [38].

The limitation of this study is that it is mainly cross-sectional and does not have longitudinal information of thyroid hormone levels and cardiac parameters, though some patients had more than one observation. Patients who were treated with beta-blockers were excluded and one can assume that beta blockade was used to mitigate the tachycardia and thus many patients with tachycardia were not captured in this study. However, the study was done in a comprehensive public health clinical setting with big central lab, and it is conceivable that...
most patients with hyperthyroidism and tachycardia were captured before the beta-blockers were started. Atrial fibrillation was not found in the study group. One explanation is that some patients are admitted to the hospital because of symptomatic atrial fibrillation and undiagnosed hyperthyroidism and are started with beta-blockade before the thyroid function tests are back and, therefore, excluded from the study. However, the purpose of this study was to evaluate the sinus tachycardia as a response to elevated thyroid hormones and not to include cardiac arrhythmias. Another limitation was the exclusion of total or free triiodothyronine (T3) levels which were unavailable for most patients. Since a minor percentage (11%) of patients with untreated thyrotoxicosis have T3 thyrotoxicosis [39], the absence of T3 testing only minimally impacts the overall result of the study.

The novelty of this study is that literature concerning the prevalence and range of variability of sinus tachycardia and PP has not been re-examined in decades. This study shows clear change in the disease manifestation most likely brought about by the current practice patterns with ease of thyroid testing and its increased usage thus allowing diagnosis of mild or asymptomatic forms of hyperthyroidism. This study shows that tachycardia is not such a common feature of hyperthyroidism today. A widened pulse pressure was a more prevalent clinical finding in this study.

Supporting information

S1 Data. Hyperthyroid tachycardia data de-identified.
(XLSX)

Author Contributions

Conceptualization: Muriel Tania Go, Amrutha Mary George, Leon Fogelfeld.
Data curation: Muriel Tania Go, Amrutha Mary George, Bettina Tahsin, Leon Fogelfeld.
Formal analysis: Muriel Tania Go, Amrutha Mary George, Bettina Tahsin, Leon Fogelfeld.
Investigation: Muriel Tania Go, Amrutha Mary George, Leon Fogelfeld.
Methodology: Muriel Tania Go, Amrutha Mary George, Leon Fogelfeld.
Project administration: Leon Fogelfeld.
Resources: Leon Fogelfeld.
Supervision: Leon Fogelfeld.
Validation: Muriel Tania Go, Amrutha Mary George, Bettina Tahsin, Leon Fogelfeld.
Visualization: Muriel Tania Go, Amrutha Mary George, Bettina Tahsin, Leon Fogelfeld.
Writing – original draft: Muriel Tania Go, Amrutha Mary George, Bettina Tahsin, Leon Fogelfeld.
Writing – review & editing: Muriel Tania Go, Amrutha Mary George, Bettina Tahsin, Leon Fogelfeld.

References

1. Vargas-Urcoeecha H, Sierra-Torres CH. Thyroid hormones and the heart. Horm Mol Biol Clin Investig 2014; 18(1):15–26. https://doi.org/10.1515/hmbci-2013-0059 PMID: 25389997
2. Davis PJ, Davis FB. Acute cellular actions of thyroid hormone and myocardial function. Ann Thorac Surg 1993; 56(1 Suppl):S16–23. https://doi.org/10.1016/0003-4975(93)80550-2 PMID: 8333793
3. Kahaly GJ, Dillmann WH. Thyroid hormone action in the heart. Endocr Rev 2005; 26(5):704–28. https://doi.org/10.1210/er.2003-0033 PMID:15632316
4. Kahaly GJ, Kampmann C, Mohr-Kahaly S. Cardiovascular hemodynamics and exercise tolerance in thyroid disease. Thyroid 2002; 12(6):473–81. https://doi.org/10.1089/105072502760143845 PMID:12165109
5. Kahaly GJ, Wagner S, Niewandt J, Mohr-Kahaly S, Ryan TJ. Stress echocardiography in hyperthyroidism. J Clin Endocrinol Metab 1999 Jul; 84(7):2308–13. https://doi.org/10.1210/jcem.84.7.5830 PMID:10404794
6. Burch H. Overview of the clinical manifestations of thyrotoxicosis. In: Braverman LE, Cooper DS, editors. Werner & Ingbar’s The thyroid: a fundamental and clinical text, 10th ed. New York, NY: Lippincott-Raven Publishers; 2013: p. 444.
7. Bischoff S, Kahaly G, Von olshausen K, et al. [Arrhythmia profile and heart rate in hyperthyroidism]. Dtsch Med Wochenschr 1988; 113(15):579–85.
8. Trzepacz PT, Klein I, Roberts M, Greenhouse J, Levey GS. Graves’ disease: an analysis of thyroid hormone levels and hyperthyroid signs and symptoms. Am J Med 1989; 87(5):558–61. https://doi.org/10.1016/s0002-9343(89)80614-x PMID:12165109
9. Roti E, Montermini M, Roti S, et al. The effect of diltiazem, a calcium channel-blocking drug, on cardiac rate and rhythm in hyperthyroid patients. Arch Intern Med 1988; 148(9):1919–21. PMID:2458079
10. Marschall K. Stoelting’s anesthesia and co-existing disease, 7th ed. USA: Elsevier; 2017.
11. Nordyke RA, Gilbert FI, Harada AS. Graves’ disease. Influence of age on clinical findings. Arch Intern Med 1988; 148(3):626–31. https://doi.org/10.1001/archinte.148.3.626 PMID:3341864
12. Arm R, Vol S, Brisac AM, Tichet J, Topouchian J. Reference values for clinic pulse pressure in a non-selected population. Am J Hypertens 2001; 14(5 Pt 1):415–8. https://doi.org/10.1016/s0895-7061(01)01294-5 PMID:11398480
13. Vinyoles E, De la sierra A, Roso-llorach A, et al. 24-h pulse pressure cutoff point definition by office pulse pressure in a population of Spanish older hypertensive patients. J Hypertens 2017; 35(5):1011–1018. https://doi.org/10.1097/HJH.0000000000001268 PMID:28182177
14. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39(33):3021–3104. https://doi.org/10.1093/eurheartj/ehy339 PMID:30165516
15. Böhm M, Schumacher H, Teo KK, et al. Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120–140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. Eur Heart J 2018; 39(33):3105–3114. https://doi.org/10.1093/eurheartj/ehy287 PMID:29873709
16. Mohr-Kahaly S, Kahaly G, Meyer J. [Cardiovascular effects of thyroid hormones]. Z Kardiol 1996; 85 Suppl 6:219–31.
17. Klein I, Ojamaa K. Thyrotoxicosis and the heart. Endocrinol Metab Clin North Am 1998; 27(1):51–62. https://doi.org/10.1016/s0889-8529(05)70297-6 PMID:9534027
18. Kahaly GJ Thyroid and the heart. Thyroid Int 1998; 4:1–21.
19. Williams RH. Thiouracil treatment of thyrotoxicosis; the results of prolonged treatment. J Clin Endocrinol Metab 1946; 6:1–22. https://doi.org/10.1210/jcem-6-1-1 PMID:21014406
20. Boelaert K, Torlinska B, Holder RL, Franklyn JA. Older subjects with hyperthyroidism present with a paucity of symptoms and signs: a large cross-sectional study. J Clin Endocrinol Metab 2010; 95(6):2715–26. https://doi.org/10.1210/jc.2009-2495 PMID:20392869
21. Shahangian S, Alspach TD, Astles JR, Yesupriya A, Dettwyler WK. Trends in laboratory test volumes for Medicare Part B reimbur sements, 2000–2010. Arch Pathol Lab Med 2014; 138(2):189–203. https://doi.org/10.5858/arpa.2013-0149-OA PMID:23738761
22. Gibbons V, Lillis S, Conaglen JV, Lawrenson R. Do general practitioners use thyroid stimulating hormone assay for opportunistic screening? N Z Med J 2009; 122(1301):25–30. PMID:19829389
23. Wheatley AM, Butkow N, Marcus RH, Lippe IT, Rosendorff C. Enhanced myocardial contractility but not tachycardia persists in isolated working hyperthyroid rat hearts. Basic Res Cardiol 1988; 83(6):634–46. https://doi.org/10.1007/BF01906958 PMID:3223880
24. Scott J, Long R, Dick R, Sherlock S. Proceedings: Percutaneous, transhepatic catheterization and sclerosis of bleeding varices. Gut 1976; 17(5):390. PMID:1084315
25. McDonough KH, Chen V, Spitzer JJ. 1987 Effect of altered thyroid status on in vitro cardiac perform ance in rats. Am J Physiol 252:H788–H795. https://doi.org/10.1152/ajpheart.1987.252.4.H788 PMID:3565593
26. Davis PJ, Davis FB. Hyperthyroidism in patients over the age of 60 years. Clinical features in 85 patients. Medicine (Baltimore) 1974; 53(3):161–81. https://doi.org/10.1097/00005792-197405000-00001 PMID: 4133091

27. Trivalle C, Doucet J, Chassagne P, et al. Differences in the signs and symptoms of hyperthyroidism in older and younger patients. J Am Geriatr Soc 1996; 44(1):50–3. https://doi.org/10.1111/j.1532-5415.1996.tb05637.x PMID: 8537590

28. Aronow WS. The heart and thyroid disease. Clin Geriatr Med 1995; 11(2):219–29. PMID: 7606991

29. Dahl P, Danzi S, Klein I. Thyrotoxic cardiac disease. Curr Heart Fail Rep 2008; 5(3):170–29. PMID: 7606691

30. Graettinger JS, Muenster J, Silverstone LA, Campbell JA. A correlation of clinical and hemodynamic studies in patients with hyperthyroidism with and without congestive heart failure. J Clin Invest 1959; 38(8):1316–27. https://doi.org/10.1172/JCI103906 PMID: 13673087

31. Fazio S, Palmieri EA, Lombardi G, Biondi B. Effects of thyroid hormone on the cardiovascular system. Recent Prog Horm Res 2004; 59:31–50. https://doi.org/10.1210/rp.59.1.31 PMID: 14749496

32. Vaccarino V, Holford TR, Krumholz HM. Pulse pressure and risk for myocardial infarction and heart failure in the elderly. J Am Coll Cardiol 2000; 36(1):130–8. https://doi.org/10.1016/s0735-1097(00)00687-2 PMID: 10029125

33. Chae CU, Pfeffer MA, Glynn RJ, Mitchell GF, Taylor JO, Hennekens CH. Increased pulse pressure and risk of heart failure in the elderly. JAMA 1999; 281(7):634–9. https://doi.org/10.1001/jama.281.7.634 PMID: 10296125

34. Larsen PR. Thyroid-pituitary interaction: feedback regulation of thyrotropin secretion by thyroid hormones. N Engl J Med 1982; 306(1):23–32. https://doi.org/10.1056/NEJM198201073060107 PMID: 7031472

35. Usala SJ, Bale AE, Gesundheit N, et al. Tight linkage between the syndrome of generalized thyroid hormone resistance and the human c-erbA beta gene. Mol Endocrinol 1988; 2(12):1217–20. https://doi.org/10.1210/mend-2-12-1217 PMID: 2905763

36. Bilezikian JP, Loeb JN. The influence of hyperthyroidism and hypothyroidism on alpha- and beta-adrenergic receptor systems and adrenergic responsiveness. Endocr Rev 1983; 4(4):378–88. https://doi.org/10.1210/edrv-4-4-378 PMID: 6317368

37. Klein I, Levey GS. New perspectives on thyroid hormone, catecholamines, and the heart. Am J Med 1984; 76(2):167–72. https://doi.org/10.1016/0002-9343(84)90768-x PMID: 6695944

38. Fitzgerald SP, Bean NG, Falhammar H, Tuke J. Clinical Parameters Are More Likely to Be Associated with Thyroid Hormone Levels than with Thyrotropin Levels: A Systematic Review and Meta-analysis. Thyroid 2020. https://doi.org/10.1089/thy.2019.0535 PMID: 32349628

39. Konrady A. [T3-thyrotoxicosis: incidence, significance and correlation with iodine intake]. Orv Hetil 2000; 141(7):337–40.